NCT07406152 Efficacy and Safety of ZKARE® Gel and Its Accessory ZKAPI® in the Treatment of Chronic Ulcers.

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 134 participants in total. It began in 2025-11-14 with a primary completion date of 2026-06.

Brief Summary

This prospective, randomized, single-blind, controlled clinical investigation evaluates the efficacy and safety of ZKARE®, a topical polymeric gel dressing, and its accessory applicator ZKAPI®, for the treatment of chronic, hard-to-heal ulcers. The study includes 134 ulcers of different etiologies-pressure ulcers, neuropathic diabetic foot ulcers, and venous leg ulcers-meeting predefined selection criteria. Participants are randomized to receive either ZKARE® in addition to standard wound care or standard care alone. The primary efficacy endpoint is the change in wound condition assessed through the RESVECH 2.0 scale, recorded at baseline and throughout treatment and follow-up visits. The primary safety endpoint is the incidence of serious adverse events (SAEs). Secondary outcomes include percentage and rate of wound closure, total closure rate, estimated time to full closure, quality-of-life measures (DLQI), patient satisfaction, investigator global assessment, cost-effectiveness, and product usability. The study aims to generate evidence on the performance, safety, and clinical usefulness of ZKARE® for chronic wound management.

Eligibility Criteria

Inclusion Criteria: * Adult patients (≥18 years). * Presence of at least one chronic hard-to-heal ulcer, including any of the following etiologies: Grade II, III or IV pressure ulcers; neuropathic diabetic foot ulcers (grade I, II or III), Wagner Grade I-III or Texas 0, I, II, III / Stage B; class C6/C6r venous leg ulcers measured with CEAP scale ; neuro-ischaemic ulcers with adequate distal perfusion (ABI/ITB ≥ 0.7-0.89; mild PAD); mixed-etiology venous ulcers and any chronic lower-limb lesion with palpable distal pulses. * Ulcer size between 1 cm² and 100 cm². * Ability and willingness to comply with all study visits and procedures according to the clinical protocol. * Ability to understand and sign the informed consent, obtained before performing any protocol-specific procedures. Exclusion Criteria: * Ulcers of etiologies not listed in the inclusion criteria. * Ischaemic, neoplastic or atypical ulcers. * Severe comorbidities judged to compromise safety or study compliance, including: severe malnutrition, palliative/terminal status, severe anemia, decompensated heart failure, chronic kidney disease stage III/IV or in dialysis. * Ulcers with moderate-severe or severe infection per PEDIS-IDSA infection grading scale. * Known allergy or sensitivity to any component of the investigational product. * Any condition that, in the investigator's opinion, may compromise patient safety or adherence to the protocol. * Pregnancy or planned breastfeeding.

Contact & Investigator

Frequently Asked Questions

Related Trials